This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:hypertension [01.04.2019]
sallieq [Notes and comments]
home:diseases:hypertension [01.04.2019] (current)
sallieq [Recent research]
Line 111: Line 111:
-{{tag>​disease symptoms ​arrange}}+The administration of olmesartan improved blood pressure, insulin, HOMA, visfatin and lipid profile in hypertensive obese women. Irbesartan improved blood pressure and lipid levels. (({{pubmed>​long:​21061834}})) 
 +Olmesartan ameliorated arterial stiffness in patients with hypertension,​ which may be involved in the reduction of serum A-FABP. ​  ​(({{pubmed>​long:​21063874}})) 
 +Given the involvement of oxidative stress and its signaling in atherogenesis,​ and the available evidence of olmesartan'​s vasoprotective,​ anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the omelsartan'​s antioxidant and anti-inflammatory potential translation,​ in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground. ​ (({{pubmed>​long:​21504378}})) 
 +{{tag>​disease symptoms }}
 ===== References ===== ===== References =====
home/diseases/hypertension.txt · Last modified: 01.04.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.